PARIS--(BUSINESS WIRE)--Waiv, formerly Owkin Dx, a company advancing AI precision testing, today announced that two of its AI precision tests, RlapsRisk® BC for breast cancer prognostic risk profiling and MSIntuit® CRC for colorectal cancer MSI screening, have each received CE marking under the European In Vitro Diagnostic Regulation (IVDR), authorising clinical deployment across EU member states. Improving Patient Outcomes Through AI-Driven Precision Testing RlapsRisk BC predicts breast cancer
2026 Copyright © News-Matic.com. All Rights Reserved
